Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137294 | 0.83 | MAP4K4 (0.42) | MAP4K4RIPK1TNIK | |
| SCHEMBL20820178 | 0.78 | MAP4K4 (0.47) | MAP4K4RIPK1TNIK | |
| SCHEMBL15740086 | 0.76 | MAP4K4 (0.46) | MAP4K4RIPK1TNIKEGLN2 | |
| SCHEMBL13075167 | 0.74 | MAP4K4 (0.44) | MAP4K4RIPK1TNIK | |
| SCHEMBL57305 | 0.74 | MAP4K4 (0.44) | MAP4K4RIPK1TNIK | |
| SCHEMBL17238976 | 0.74 | MAP4K4 (0.44) | MAP4K4RIPK1TNIKEGLN2 | |
| SCHEMBL64667 | 0.74 | MAP4K4 (0.44) | MAP4K4RIPK1TNIKEGLN2 | |
| SCHEMBL21539219 | 0.72 | PI4KA (0.33) | MAP4K4 | |
| SCHEMBL19402915 | 0.70 | MAP4K4 (0.41) | MAP4K4RIPK1TNIK | |
| SCHEMBL12392887 | 0.70 | RET (0.41) | MAP4K4RIPK1TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | MAP4K4 2610/4885RIPK1 585/4885TNIK 2864/4885 |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | MAP4K4 2573/4885RIPK1 623/4885TNIK 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.